Jewish General Hospital
Montreal QC H3T 1E2
8 studies enrolling now · 26 studies all time
What they study most
Abdominal Surgery, Acute Myeloid Leukemia, Anaplastic Large-Cell Lymphoma, Breast Neoplasms, Cachexia, Chronic Lymphocytic Leukemia, Endometrial Cancer, Fallopian Tube Neoplasms, GIST, Gastro-enteropancreatic Neuroendocrine Tumor, HER2 Positive Breast Cancer, Heparin-induced Thrombocytopenia
Studies at this site
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer — Recruiting now
- CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) — Recruiting now
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer — Recruiting now
- A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 — Recruiting now
- Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy — Recruiting now
- Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma — Recruiting now
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer — Recruiting now
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET — Running, not enrolling
- A Study of KITE-363 in Participants With Refractory Autoimmune Diseases — Enrolling by invitation
- Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread — Completed
- Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors — Running, not enrolling
- Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma — Running, not enrolling
- A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer — Running, not enrolling
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) — Running, not enrolling
- Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma — Running, not enrolling
- Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) — Running, not enrolling
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
- Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy — Completed
- Development of a Patient-Reported Outcome Measure to Assess Recovery After Abdominal Surgery — Running, not enrolling
- Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) — Completed
- ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients — Completed
- A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer — Completed
- Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban — Stopped early
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST — Completed
- ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas — Completed
- Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer — Completed